KBI Biopharma, Inc. is a global contract development and manufacturing organization (CDMO) that provides fully integrated drug development and biomanufacturing services to life science companies bringing new medicines and vaccines to patients. The company is headquartered in Durham, North Carolina, and operates facilities across its global network. It has been active for nearly three decades and received top honors in the 2025 CDMO Leadership Awards.
Its technical work spans mammalian cell line and process development, microbial expression systems, cell line development, process development, analytical development, formulation development, biologics characterization, and clinical and commercial biomanufacturing, alongside vaccine development and manufacturing. Two proprietary technology platforms underpin this work: the SUREtechnology Platform, used for mammalian systems in biopharmaceutical development and manufacturing, and the PUREplatform, applied to microbial expression systems.
KBI Biopharma is part of the JSR Life Sciences group. The company describes an emphasis on combining deep scientific expertise with operational excellence, and an integrated, partner-oriented approach that guides clients from early-stage development through to commercial manufacturing, with a focus on accelerating timelines from discovery to patient.
